Nonalcoholic Fatty Liver Disease and Cardiovascular Disease: Has the Time Come for Cardiologists to Be Hepatologists?
Nonalcoholic fatty liver disease (NAFLD) is prevalent in people with the metabolic syndrome and type 2 diabetes and is present in up to one-third of the general population. Evidence is now accumulating that NAFLD is associated with obesity and diabetes and may serve as a predictor of cardiovascular...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2012-01-01
|
| Series: | Journal of Obesity |
| Online Access: | http://dx.doi.org/10.1155/2012/483135 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850237359746973696 |
|---|---|
| author | Mohamed H. Ahmed Salma Barakat Ahmed O. Almobarak |
| author_facet | Mohamed H. Ahmed Salma Barakat Ahmed O. Almobarak |
| author_sort | Mohamed H. Ahmed |
| collection | DOAJ |
| description | Nonalcoholic fatty liver disease (NAFLD) is prevalent in people with the metabolic syndrome and type 2 diabetes and is present in up to one-third of the general population. Evidence is now accumulating that NAFLD is associated with obesity and diabetes and may serve as a predictor of cardiovascular disease (CVD). The possible mechanisms linking NAFLD and CVD include inflammation and oxidative stress, hyperlipidaemia, insulin resistance, and direct impact of NAFLD on coronary arteries and left ventricular dysfunction. In addition, several studies suggest that NAFLD is associated with high risk of CVD and atherosclerosis such as carotid artery wall thickness and lower endothelial flow-mediated vasodilation independently of classical risk factors and components of the metabolic syndrome. It is not yet clear how treatment of NAFLD will modulate the risk of CVD. Furthermore, studies are urgently needed to establish (i) the pathophysiology of CVD with NAFLD and (ii) the benefit of early diagnosis and treatment of CVD in patients with NAFLD. In the absence of biochemical markers, it is crucial that screening and surveillance strategies are adopted in clinical practice in the growing number of patients with NAFLD and at risk of developing CVD. Importantly, the current evidence suggest that statins are safe and effective treatment for CVD in individuals with NAFLD. |
| format | Article |
| id | doaj-art-021f3b62236b43049f9407df108d0308 |
| institution | OA Journals |
| issn | 2090-0708 2090-0716 |
| language | English |
| publishDate | 2012-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Obesity |
| spelling | doaj-art-021f3b62236b43049f9407df108d03082025-08-20T02:01:46ZengWileyJournal of Obesity2090-07082090-07162012-01-01201210.1155/2012/483135483135Nonalcoholic Fatty Liver Disease and Cardiovascular Disease: Has the Time Come for Cardiologists to Be Hepatologists?Mohamed H. Ahmed0Salma Barakat1Ahmed O. Almobarak2Department of Medicine, Wexham Park Hospital, Berkshire, Slough, UKNational Center for GI & Liver Diseases, Ibn Sina Hospital, Ministry of Health, Khartoum, SudanDepartment of Pathology, Faculty of Medicine, University of Medical Sciences and Technology, Khartoum, SudanNonalcoholic fatty liver disease (NAFLD) is prevalent in people with the metabolic syndrome and type 2 diabetes and is present in up to one-third of the general population. Evidence is now accumulating that NAFLD is associated with obesity and diabetes and may serve as a predictor of cardiovascular disease (CVD). The possible mechanisms linking NAFLD and CVD include inflammation and oxidative stress, hyperlipidaemia, insulin resistance, and direct impact of NAFLD on coronary arteries and left ventricular dysfunction. In addition, several studies suggest that NAFLD is associated with high risk of CVD and atherosclerosis such as carotid artery wall thickness and lower endothelial flow-mediated vasodilation independently of classical risk factors and components of the metabolic syndrome. It is not yet clear how treatment of NAFLD will modulate the risk of CVD. Furthermore, studies are urgently needed to establish (i) the pathophysiology of CVD with NAFLD and (ii) the benefit of early diagnosis and treatment of CVD in patients with NAFLD. In the absence of biochemical markers, it is crucial that screening and surveillance strategies are adopted in clinical practice in the growing number of patients with NAFLD and at risk of developing CVD. Importantly, the current evidence suggest that statins are safe and effective treatment for CVD in individuals with NAFLD.http://dx.doi.org/10.1155/2012/483135 |
| spellingShingle | Mohamed H. Ahmed Salma Barakat Ahmed O. Almobarak Nonalcoholic Fatty Liver Disease and Cardiovascular Disease: Has the Time Come for Cardiologists to Be Hepatologists? Journal of Obesity |
| title | Nonalcoholic Fatty Liver Disease and Cardiovascular Disease: Has the Time Come for Cardiologists to Be Hepatologists? |
| title_full | Nonalcoholic Fatty Liver Disease and Cardiovascular Disease: Has the Time Come for Cardiologists to Be Hepatologists? |
| title_fullStr | Nonalcoholic Fatty Liver Disease and Cardiovascular Disease: Has the Time Come for Cardiologists to Be Hepatologists? |
| title_full_unstemmed | Nonalcoholic Fatty Liver Disease and Cardiovascular Disease: Has the Time Come for Cardiologists to Be Hepatologists? |
| title_short | Nonalcoholic Fatty Liver Disease and Cardiovascular Disease: Has the Time Come for Cardiologists to Be Hepatologists? |
| title_sort | nonalcoholic fatty liver disease and cardiovascular disease has the time come for cardiologists to be hepatologists |
| url | http://dx.doi.org/10.1155/2012/483135 |
| work_keys_str_mv | AT mohamedhahmed nonalcoholicfattyliverdiseaseandcardiovasculardiseasehasthetimecomeforcardiologiststobehepatologists AT salmabarakat nonalcoholicfattyliverdiseaseandcardiovasculardiseasehasthetimecomeforcardiologiststobehepatologists AT ahmedoalmobarak nonalcoholicfattyliverdiseaseandcardiovasculardiseasehasthetimecomeforcardiologiststobehepatologists |